Gate 4
Jun 2026
Go w/ conditions
Stage 4
Phase 3
You are here
Vitalis Therapeutics Inc. — The criteria against which every gate in the VitaFlow (VTX-401) program is decided: the two-tier must-meet and should-meet model, the scoring scale, the evidence standard, and the full criteria set for all seven gates. Operates alongside the Development Committee Charter, which defines who decides.
1. The Two-Tier Model
Every gate assesses two kinds of criteria, and they behave differently on purpose.
| Tier | Nature | Effect of a shortfall |
|---|
| Must-meet | Binary. Satisfied or not. | An unsatisfied must-meet cannot produce a GO. The outcome is RECYCLE if remediable, KILL if not. It is not outvotable — a majority cannot vote a criterion into satisfaction. |
| Should-meet | Scored 1–5 against a defined scale. | Scores at threshold (3) produce conditions. Scores below threshold drive RECYCLE. Scores at 4 or 5 carry no consequence. |
Why the tiers are separated. A single blended score lets a strong commercial case
compensate for a weak safety package. Separating them prevents that arithmetic: no amount of
commercial upside converts an unsatisfied must-meet into a pass, because the two tiers do not
share a scale.
2. Scoring Scale
| Score | Meaning |
|---|
| 5 | Fully satisfied. Evidence complete and independently verifiable. |
| 4 | Satisfied. Minor gaps that do not affect the decision. |
| 3 | Threshold. Satisfiable inside the next stage — the score that produces a condition rather than a failure. |
| 2 | Materially short. Drives RECYCLE unless a must-meet is also unsatisfied. |
| 1 | Absent. No credible evidence tabled. |
The threshold score is 3. It is deliberately defined as “satisfiable inside the
next stage” rather than “adequate”, because the question a gate asks about a
should-meet criterion is not whether the position is good — it is whether the gap can be
closed with work the program is about to do anyway.
3. Evidence Standard
A criterion is assessed on evidence tabled at the gate, not on assurance given at the gate.
The Chair certifies that what has been tabled meets the standard; the Committee decides what it
means.
| Acceptable | Not acceptable |
|---|
| Signed reports, agency minutes, validated datasets | Verbal summary of a report not yet issued |
| Executed contracts and dated commitments | Draft agreements and expressions of intent |
| Data from the running study | Extrapolation from an earlier phase |
| Independent verification where the criterion is contested | Self-assessment by the owning function alone |
Assertion is not evidence. “The team is confident enrolment will recover” is an
assertion. A site activation schedule with dated commitments and a screen-failure rate from the
running study is evidence. Where only assertion is available, the criterion scores 1 — not
3 with a caveat.
4. Gate Criteria
Criteria are set when a gate is defined and are not revised inside the stage that leads to it.
A criterion the program discovers it cannot meet is a matter to escalate, not a matter to
rewrite.
Gate 0 — Candidate Selection — 01 Mar 2022 · GO (6-0)
Must-meet
| Ref | Criterion |
|---|
| M1 | Target validated in at least two independent models |
| M2 | Freedom-to-operate opinion obtained |
| M3 | Candidate meets the minimum target product profile |
Should-meet
| Ref | Criterion | Score |
|---|
| S1 | Differentiation against approved products in the class | 4 |
| S2 | Projected development cost within portfolio tolerance | 4 |
| S3 | Commercial case supports the therapeutic area | 5 |
Gate 1 — IND-Enabling Readiness — 31 Dec 2022 · GO (5-1)
Must-meet
| Ref | Criterion |
|---|
| M1 | GLP toxicology package complete and supportive of first-in-human |
| M2 | Drug substance route defined and reproducible at scale |
| M3 | Regulatory strategy agreed and pathway confirmed |
Should-meet
| Ref | Criterion | Score |
|---|
| S1 | Analytical methods qualified | 3 |
| S2 | Drug product formulation stable to the required shelf life | 4 |
| S3 | Clinical development plan costed and resourced | 4 |
Gate 2 — IND Submission — 30 Jun 2023 · GO (6-0)
Must-meet
| Ref | Criterion |
|---|
| M1 | IND submitted and accepted — thirty-day review clear |
| M2 | Phase 1 protocol final and IRB-approved |
| M3 | Clinical supply released to specification |
Should-meet
| Ref | Criterion | Score |
|---|
| S1 | Investigator sites contracted | 4 |
| S2 | Pharmacovigilance system operational | 5 |
Gate 3 — Phase 2 Readiness — 31 May 2024 · GO (6-0)
Must-meet
| Ref | Criterion |
|---|
| M1 | Phase 1 safety and tolerability support continued development |
| M2 | Pharmacokinetic profile supports the intended dosing interval |
| M3 | Phase 2 protocol final, dose span justified |
Should-meet
| Ref | Criterion | Score |
|---|
| S1 | Phase 2 sites identified and activation sequenced | 4 |
| S2 | CMC capacity adequate for Phase 2 supply | 4 |
| S3 | Competitive landscape unchanged in a material way | 3 |
Gate 4 — Phase 3 Initiation — 30 Jun 2026 · GO WITH CONDITIONS (5-0-1)
Must-meet
| Ref | Criterion |
|---|
| M1 | Phase 2 efficacy demonstrated at a dose with acceptable tolerability |
| M2 | End-of-Phase-2 meeting held; pivotal design and endpoints agreed with the agency |
| M3 | Phase 3 protocol final and statistically powered to the agreed endpoints |
| M4 | Manufacturing plan supports registration-batch timing |
Should-meet
| Ref | Criterion | Score |
|---|
| S1 | CMC readiness — analytical method transfer complete | 3 |
| S2 | Market access evidence plan in place | 3 |
| S3 | Phase 3 site and enrolment plan credible against the curve | 4 |
| S4 | Business case clears the hurdle on refreshed assumptions | 4 |
Three should-meet criteria scored 3 at Gate 4 — CMC method transfer, market access evidence, and (at 4) the enrolment plan. The two scored at threshold produced GC-01 and GC-03. This is the framework working as designed: the gate carried, and the two weakest areas were converted into dated, owned, verifiable obligations rather than absorbed as optimism.
Gate 5 — NDA Submission — 30 Sep 2028 · pending
Must-meet
| Ref | Criterion |
|---|
| M1 | Both pivotal trials met the co-primary endpoints |
| M2 | Safety database complete and integrated summaries drafted |
| M3 | Registration batches manufactured, on stability, process validation complete |
| M4 | Pre-NDA meeting held and content agreed |
Should-meet
| Ref | Criterion | Score |
|---|
| S1 | Labeling strategy aligned to the data | not yet assessed |
| S2 | Launch supply plan credible against the action date | not yet assessed |
| S3 | Payer evidence package complete | not yet assessed |
Gate 5 is the next gate. Should-meet criteria are recorded but not yet scored; scoring happens at the gate on evidence tabled, not in advance. Open items carried against them are tracked in the Gate Conditions Register, and live position against every criterion is maintained in the Gate 5 Readiness Assessment.
Gate 6 — Approval & Launch — 11 Oct 2029 · pending
Must-meet
| Ref | Criterion |
|---|
| M1 | Approval granted |
| M2 | Pre-approval inspection closed with no unresolved deficiency |
| M3 | Launch supply released and in distribution |
Should-meet
| Ref | Criterion | Score |
|---|
| S1 | Field force trained and deployed | not yet assessed |
| S2 | Payer coverage secured in the launch accounts | not yet assessed |
5. How an Outcome Is Derived
- Assess must-meets first. If any is unsatisfied, the outcome is RECYCLE or KILL and the
should-meet scoring is not reached. This ordering matters: scoring first invites the committee to
weigh a strong overall picture against a specific unmet obligation.
- Score should-meets against §2, on evidence per §3.
- Derive the outcome. All must-meets satisfied and no should-meet below 4 →
GO. All must-meets satisfied with one or more should-meets at 3 → GO WITH
CONDITIONS, one condition per criterion at threshold. Any should-meet at 2 or below →
RECYCLE.
- Record. The score sheet is part of the minutes and is not amended after approval.
The outcome is derived, not negotiated. The Committee's judgment is exercised in the
scoring — which is where judgment belongs — not in the step from scores to outcome.
Once the scores are recorded the outcome follows mechanically, which is what stops a gate from
becoming a negotiation about how much the program would like to proceed.
6. Worked Example — the Gate 4 Score Sheet
The framework above describes machinery. This section runs it, using the actual Gate 4 decision
of 30 June 2026.
Step 1 — Must-meet assessment
| Ref | Criterion | Evidence tabled | Assessment |
|---|
| M1 | Phase 2 efficacy demonstrated at a dose with acceptable tolerability | Locked Phase 2 dataset; primary and secondary endpoint analyzes; discontinuation rates by dose arm | satisfied |
| M2 | End-of-Phase-2 meeting held; pivotal design and endpoints agreed with the agency | Official minutes, 19 May 2026; agreed co-primary endpoints; CV safety expectation recorded | satisfied |
| M3 | Phase 3 protocol final and statistically powered to the agreed endpoints | Final protocol v1.0; statistical analysis plan; power calculation at 90% for both co-primaries | satisfied |
| M4 | Manufacturing plan supports registration-batch timing | CMC plan with registration-batch schedule; Aldergate capacity confirmation | satisfied |
All four satisfied. The gate proceeds to scoring. Had any been unsatisfied, scoring would not
have occurred — the ordering at §5 exists precisely so that a strong overall picture
cannot be weighed against a specific unmet obligation.
Step 2 — Should-meet scoring
| Ref | Criterion | Score | Basis |
|---|
| S1 | CMC readiness — analytical method transfer complete | 3 | Two of three methods re-qualified at Aldergate; the third in progress with a dated plan. Closeable inside Stage 4, so threshold rather than below. |
| S2 | Market access evidence plan in place | 3 | Evidence plan drafted; payer advisory board program scoped but not scheduled. Work identified, not started. |
| S3 | Phase 3 site and enrolment plan credible against the curve | 4 | Site list with activation sequence and a reserve list; recruitment rates carried forward from Phase 2 with a stated haircut. |
| S4 | Business case clears the hurdle on refreshed assumptions | 4 | Refreshed model returns 43.6% against a 15.0% hurdle. Minor gap: gross-to-net assumptions not re-tested against the latest payer landscape. |
Step 3 — Outcome derivation
All must-meets satisfied; two should-meets at threshold. Per §5 the outcome is
GO WITH CONDITIONS, with one condition per criterion at threshold. Nothing here is a
judgment call at this step — the judgment was exercised in the scoring.
| Threshold criterion | Condition issued | Owner | Due |
|---|
| S1 — CMC method transfer | GC-01 — complete re-qualification for all three methods | Dr. K. Oyelaran | 18 Dec 2026 |
| S2 — Market access evidence | GC-03 — stand up the payer evidence plan and hold first advisory boards | J. Barrington | 31 Mar 2027 |
GC-02 was also issued at this gate, but not from a threshold score — it arose from
the CR-02 scope addition approved shortly before, and attaches the DMC protocol confirmation to
the sub-study. Conditions may be issued for reasons other than a threshold score; a threshold
score must always produce one.
Step 4 — The vote
Recorded outcome: GO WITH CONDITIONS (5-0-1). Five voting seats, four in favour, one abstention. The
abstention was recorded by the Chief Financial Officer against S4 — specifically the
un-refreshed gross-to-net assumptions — on the basis that a
$125,800,000 release warranted a fully re-tested commercial model rather than one with a
stated minor gap.
The abstention was not overruled and did not block the gate. It is part of the permanent
record, and it is the reason the business case refresh carries a standing item at Gate 5. An
abstention is a statement that a member cannot support the decision on the evidence tabled
— recording the reason is what makes it useful eighteen months later, when the question of
whether the commercial case was tested becomes live again.
7. What a RECYCLE Would Have Looked Like
Gate 4 carried. It is worth setting out what the same gate would have produced had the evidence
been weaker, because a framework is only meaningful if the failure paths are as well defined as
the success path.
Scenario — M1 unsatisfied
Suppose the Phase 2 dataset had shown efficacy at the top dose but with a discontinuation rate
materially above the modelled figure, such that no dose demonstrated efficacy with acceptable
tolerability. M1 is then unsatisfied.
| Step | What happens |
|---|
| Scoring | Does not occur. The must-meet assessment terminates the gate. |
| Outcome | RECYCLE — the criterion is unsatisfied but remediable: an extended dose-escalation schedule is work the program can actually perform. |
| Tranche | The $125,800,000 Stage 4 tranche does not release. Phase 3 does not start, and no CRO Phase 3 work package is authorized. |
| Remediation scope | Chair produces it within ten working days: a tolerability sub-study on a revised escalation schedule, its cost, its owner, and the date Gate 4 re-convenes. |
| Funding | From contingency, against a named draw. The cost of the recycle is therefore visible in the Program Budget rather than absorbed. |
| Roster | Retained. Releasing and rebuilding a 109-person program team costs more than carrying it through a remediation window. |
| Agency | The End-of-Phase-2 position may require revisiting, since dose selection was agreed on the superseded data. This is usually the longest pole in a recycle, not the clinical work itself. |
Why this scenario matters more than the one that happened. A committee with no RECYCLE
option facing an unsatisfied M1 has two usable choices: pass anyway on an understanding that
tolerability will be managed in Phase 3, or kill an asset that has cleared every other criterion.
It will choose to pass, and the program will discover in Phase 3 — at
$125,800,000 rather than at the cost of a sub-study — what it could have learned
first.
8. Evidence Packs
Each criterion is assessed on a defined evidence pack, submitted at day −20 per the gate
preparation timetable in the
Development Committee Charter. Pack contents are fixed when
the gate is defined.
| Gate | Evidence pack contents |
|---|
| Gate 0 | Target validation data from two independent models; freedom-to-operate opinion; target product profile; indicative development cost and timeline. |
| Gate 1 | GLP toxicology study reports; drug substance route and reproducibility data; formulation stability data; regulatory strategy document; costed clinical development plan. |
| Gate 2 | IND submission receipt and thirty-day clearance; final Phase 1 protocol with IRB approvals; certificate of analysis and release documentation for clinical supply; executed site contracts; pharmacovigilance system master file. |
| Gate 3 | Phase 1 clinical study report; PK/PD analysis; final Phase 2 protocol with dose justification; site activation plan; CMC supply plan for Phase 2. |
| Gate 4 | Locked Phase 2 dataset and analyzes; End-of-Phase-2 official minutes; final Phase 3 protocol and statistical analysis plan; power calculation; CMC plan with registration-batch schedule; refreshed business case model; site and enrolment plan. |
| Gate 5 | Clinical study reports for both pivotals; integrated summaries of safety and efficacy; registration-batch release and stability data; process validation report; Pre-NDA meeting minutes; draft labeling; launch supply plan. |
| Gate 6 | Approval letter; pre-approval inspection close-out; batch release documentation; distribution readiness confirmation; field deployment and training records; payer coverage position in launch accounts. |
A pack is a list of documents, not a presentation. Slides may be used to walk the Committee
through the pack; they are not themselves evidence, and a criterion supported only by a slide is
supported only by assertion (§3).
9. Criteria Change Control
Criteria are set when a gate is defined and are not revised inside the stage leading to it.
- A criterion may be added at any time by Committee decision, minuted, where a new
obligation arises — a regulatory expectation, a change in the competitive or safety
landscape.
- A criterion may not be removed or weakened inside the stage that leads to the gate it
governs. Removal requires a Committee decision taken at least one full stage before the gate,
which makes it impossible to remove a criterion the program is currently failing.
- Evidence-pack contents may be clarified but not reduced. A clarification specifies what
form evidence must take; a reduction changes what must be shown.
- Every change is recorded with the date, the rationale, and the gate from which it takes
effect.
The one-stage rule is the whole provision. Without it, a program approaching a gate it will
not pass has an obvious and entirely rational move: propose a criteria revision. The revision will
be well-argued, the reasoning will be sound, and the gate will be rendered meaningless. Requiring
a full stage of separation removes the option at exactly the moment it becomes tempting.